ARCA biopharma, Inc. (NASDAQ: ABIO) today announced the completion of enrollment for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE